Propeller Health acquired by ResMed for $225M

FierceHealthcare | December 03, 2018

A Wisconsin-based startup that makes digital inhalers has been purchased by medical device giant ResMed for $225 million. Propeller Health, which bills itself as the “leading digital therapeutics company” created a digital inhaler to help patients with chronic obstructive pulmonary disease (COPD), a disease that impacts 16 million Americans. ResMed CEO Mick Farrell called the purchase a “significant step for ResMed towards becoming the global leader in digital health for COPD.” ResMed has manufactured more than 6 million cloud-connected remote monitoring devices, with a focus on sleep apnea and respiratory illnesses.

Spotlight

Angiogenesis is a vital process that occurs during normal development, growth, and wound healing. However, it is also implicated in the growth of cancer, through the tumor’s ability to release chemical signals that stimulate angiogenesis.

Spotlight

Angiogenesis is a vital process that occurs during normal development, growth, and wound healing. However, it is also implicated in the growth of cancer, through the tumor’s ability to release chemical signals that stimulate angiogenesis.

Related News

HEALTH TECHNOLOGY

Carbon Health Announces the launch of COVID-19 Vaccination Platform to Accelerate National Rollout

Carbon Health | January 18, 2021

Carbon Health, the innovation empowered healthcare supplier, declared today the dispatch of Carbon Health Vaccinate, a platform that permits neighborhood governments to all the more effectively oversee antibody activities, and for any individual to effortlessly check their qualification for a COVID-19 immunization and pursue a vaccination arrangement. The organization likewise reported its first association with the City of Los Angeles and CORE (Community Organized Relief Effort) to help the city's COVID-19 vaccination program, giving administration innovation, and authoritative oversight to help stem the pandemic and increment vaccination limit in Los Angeles to an extra 20,000 individuals per day. This organization and the new vaccination innovation arrangement will permit the City of L.A. - and others across the U.S. - to quicken the antibody rollout during a urgent time in the COVID-19 pandemic. The vaccine rollout across the country has been frustratingly slow for medical providers and individuals alike, particularly as COVID-19 cases surge in L.A. and across the country. As we witnessed with testing, there has been limited national support, and local governments are bogged down by demand and logistics,” said Eren Bali, co-founder and CEO of Carbon Health. “The City of L.A., the LA Fire Department, and CORE have been doing an incredible job setting up vaccination programs, and, with our technology and clinical support, we should be able to accelerate access to the vaccine and ultimately help reduce COVID-19 casualties.” Carbon Health Vaccinateis the first comprehensive, HIPAA-compliant healthcare infrastructure platform that can help local governments efficiently and effectively compute vaccine eligibility and manage vaccination operations. Features include: High-volume appointment scheduling and queueing, including the ability to easily capture no-show appointments in order to adjust vaccine supply and use accordingly Proof of vaccination to patients and to state and county immunization registries Soon-to-launch auto-generated HIPAA-compliant digital vaccine card, theCarbon Health Pass, that displays vaccination details Automated patient reminders for 2nd dose appointments Management of waitlist and appointment bookings based on eligibility requirements For individuals, Carbon Health Vaccinate permits anybody to affirm their qualification, join to get an antibody, plan first and second portion immunization arrangements, and get their Carbon Health Pass with vaccination subtleties. As a brought together, coordinated framework, Carbon Health's platform rearranges the capacity for individuals to pursue an immunization. It is as of now accessible in Los Angeles, and qualified patients can book arrangements for immunizations across a few areas, including Dodger Stadium. “Vaccines are the key to defeating this pandemic, saving lives, and charting a course to recovery,” said Los Angeles Mayor Eric Garcetti. “With Carbon Health’s partnership and with the opening of our Dodger Stadium site, we will soon be able to deliver 20,000 vaccinations per day -- and get a growing number of Angelenos protected from this virus as quickly, safely, and efficiently as possible.” “Carbon Health is creating a key component – end-to-end registration and health records, which is essential to vaccine distribution,” said CORE Co-Founder and CEO Ann Lee. “As cases continue to rise in Los Angeles, and across the country, it’s essential to simplify and optimize the vaccination process for all communities, especially those who may not have access to smartphones or internet. CORE is proud to embark on this next phase of protecting and healing our communities, and we are working with our partners across the country to ensure safe and equitable distribution of the vaccine.” “Throughout the COVID-19 pandemic, the men and women of the LAFD have been on the front lines; both caring for patients and assisting our partners with an unprecedented testing effort,” said LAFD Fire Chief Ralph Terrazas. “As we pivot deeper into the vaccination effort, Carbon Health’s clinical and technology support is a welcome addition to the City’s partnership in the battle against this deadly virus.” About Carbon Health Carbon Health is the leading national healthcare provider with a mission to bring world-class healthcare to everyone. Leveraging its unique technology platform, Carbon Health provides its patients withomnichannel care: seamless care from the same trusted providers at a wide variety of access points, including clinics, pop-up sites, video, the Carbon Health app, and on-site at their employers. Carbon Health also provides value-based care to enterprise partners across a broad range of industries, including academia, sports, entertainment, biotechnology, and travel.

Read More

HEALTH TECHNOLOGY

FINVASIA Acquires Gini Health, a health-tech company, and expands Into Healthcare Services

FINVASIA | November 01, 2021

FINVASIA, today, announced its investment in Gini Health, a Canada based healthcare technology company that pioneered DNA and lifestyle data based personalized health to prevent diseases. This acquisition furthers FINVASIA’s strategic business objectives of investing in traditional business and transforming them. The partnership supports FINVASIA’s commitment to health care to accelerate technology-led innovation in preventive and personalized healthcare services.Effective immediately, all the previous investors have exited, making FINVASIA and Gini Health’s founder and CEO Gurjot Narwal key stakeholders in the company. This move by FINVASIA is a step towards making the company’s capital structure lean, providing them more room to support their business strategy. Gini Health’s founder and CEO Gurjot Narwal will keep leading the company. Finvasia along with the investment will provide group resources, operational experience, technology, infrastructure, and its reach as a multidisciplinary, multinational organization. “We’re excited to partner with Gini Health and this investment is a cornerstone of our strategy to fuel our pipeline with healthcare innovation. Together, we’ll bring tech driven personalised and long-term health care to people at a time when health is top-of-mind for all of us. This investment executes on FINVASIA’s commitment to transform healthcare access and delivery.” Sarvjeet Singh, Co-founder Finvasia It’s been an impressive year and half for FINVASIA, with its robust investments in many diverse sectors including financial services, fintech and healthcare. Given the global interest in healthcare services post COVID, Gini Health has been one of the most significant areas of investment for the group. “Health industry is going through a massive transformation and Gini Health has been leading this with its approach to use health data and technology to empower users to get positive health outcomes,” said Gurjot Narwal, CEO & Founder Gini Health. “FINVASIA is a successful conglomerate that harnesses technology to drive innovation and transform industries. Partnering with FINVASIA brings two passionate and innovative companies together to accelerate transformation in healthcare at a global level,” he added. “With this deal, we have got investment and resources to write the next chapter of growth and innovation. Stay tuned for our big new product announcements.” About FINVASIA Finvasia is a global enterprise that owns multiple brands in financial services, fintech, blockchain, real-estate, healthcare and technology sectors. The group invests in technology-oriented businesses and products and is committed to drive sustainable development and generate a positive impact with its businesses. Finvasia, along with its subsidiaries and sister concerns, is registered with a gamut of regulatory bodies across the world in various capacities. About Gini Health Gini Health is a Canada based health-tech company that serves customers across North America and Europe. Gini Health has received various awards and accolades for its personalized healthcare approach in preventive health care. Gini was invested by global VCs like TechStars, Rangle, Uken among others. It has grown into a digital healthcare services company with the launch of its first chronic healthcare management program.

Read More

HEALTH TECHNOLOGY

Tegria Acquires KenSci in Order to Assist Healthcare Organizations in Gaining New Insights from Data

Tegria | June 28, 2021

Tegria announced today the purchase of KenSci, a leader in artificial intelligence systems and healthcare applications with origins in Microsoft's Azure4Research program and the University of Washington. KenSci, which was founded in 2015, has received recognition for its AI platform and solutions that integrate the latest descriptive and predictive analytics technology, assisting healthcare organizations in modernizing their workflows and powering a digital, data-driven, value-based healthcare system. Customers of KenSci, which include providers, payers, and medical device manufacturers, are using advanced analytics and artificial intelligence in their operational, clinical, and care workflows, thus enhancing care experiences and health outcomes. KenSci applications are based on responsible and explainable AI models that aid in making healthcare more efficient, fair, and accountable. Its services are cloud-based and built on Microsoft Azure. Customers of KenSci have also benefitted from the company's strong relationships with industry leaders. In 2020, Microsoft honored KenSci, its US Healthcare Partner of the Year. "Unlocking data to provide insights is the key to making healthcare better for everyone," said Wasif Rasheed, Providence's chief revenue and growth officer. Tegria is set to debut in October 2020. "KenSci has been assisting clients in getting more out of their data for many years, and they understand the critical roles that innovation and collaboration play in accelerating change across all aspects of care. KenSci, when combined with Tegria's industry expertise and a wide variety of solutions, has the potential to have a significant effect on healthcare worldwide. KenSci has arrived in Tegria, and we couldn't be happier." KenSci's AI-powered platform draws insights from data, resulting in improved patient experiences, more accurate diagnoses, and more efficient processes. KenSci automates data preparation across many sources, including real-time and unstructured data, and maps it into the industry-standard schema, preparing it for machine learning models. KenSci's platform is also designed to be versatile and customizable, allowing clients to build their applications. "If you can predict, you have the potential to influence and enhance health outcomes," stated Sudarshan Chitre, CEO of KenSci. "AI and advanced analytics technologies are changing how healthcare companies use data to enhance human health and care outcomes. Tegria will allow us to expedite this transition on a larger scale while also providing instant value to our clients via AI-driven insights. We are thrilled to be joining Tegria so that we may write the next chapter together." KenSci's technology is supported by substantial peer-reviewed research published by The Institute of Electrical and Electronics Engineers (IEEE), The Association for Computing Machinery (ACM), The American Medical Informatics Association (AMIA), and other organizations. KenSci received HIMSS Health Innovation Awards in 2018 and 2019 and KLAS top ratings in healthcare AI in 2019 and 2020. KenSci was a Gartner Cool Vendor and a CMS AI Challenge finalist in 2019. KenSci is headquartered in Seattle and has offices in Singapore and India. With KenSci, Tegria can expand the breadth and depth in electronic health record optimization, managed services, revenue cycle management, and other areas. KenSci will continue to serve its existing client base while also working with its new colleagues on integrated solutions for the global healthcare industry. Tegria's financial advisor was Cascadia Capital, and its legal counsel was McDermott Will & Emery on this deal. Brentwood Capital Advisors served as the exclusive financial adviser for KenSci, while Wilson Sonsini Goodrich & Rosati acted as legal counsel. About Tegria Tegria, founded by Providence, is dedicated to creating health for a better world. Tegria assists healthcare organizations of all sizes in accelerating technological, clinical, and operational advancements that enable people to live the healthiest lifestyles possible. Tegria is a Seattle-based company with employees throughout the United States and internationally. It employs over 3,000 strategists, technologists, service providers, and scientists committed to providing value to customers.

Read More